Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGOPMK)

Drug Name

Otamixaban Drug Info

Synonyms

Methyl 2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-4-yl)benzoyl]amino]butanoate; Methyl (2R,3R)-2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-1-ium-4-yl)benzoyl]amino]butanoate; 2-(3-Carbamimidoylbenzyl)-3-(4-(1-oxypyridin-4-yl)benzoylamino)butyric acid methyl ester

Indication

Disease Entry	ICD 11	Status	REF
Angina pectoris	BA40	Discontinued in Phase 3	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Preclinical	[2]

Cross-matching ID

PubChem CID: 5496659
CAS Number: CAS 193153-04-7
TTD Drug ID: DMGOPMK

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Coagulation factor Xa (F10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apixaban	DM89JLN	Thrombosis	DB61-GB90	Approved	[4]
Rivaroxaban	DMQMBZ1	Deep vein thrombosis	BD71	Approved	[5]
DU-176b	DMCIJBH	Atrial fibrillation	BC81.3	Approved	[6]
Emicizumab	DM0AQ83	Factor VIII deficiency	3B10	Approved	[7]
BETRIXABAN	DM2C4RF	Venous thromboembolism	BD72	Approved	[8]
Lmw heparin	DMJPD06	Coagulation defect	3B10.0	Approved	[9]
Nadroparin calcium	DMBNKST	Coagulation defect	3B10.0	Approved	[10]
Fondaparinux sodium	DMWS3FH	Deep vein thrombosis	BD71	Approved	[11]
Danaparoid	DM6CLBN	Deep venous clot	BD71	Approved	[12]
Coagulation Factor IX	DM8HBJI	Haemophilia B	3B11.0	Approved	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor Xa (F10)	TTCIHJA	FA10_HUMAN	Inhibitor	[3]
HUAMN serine protease factor Xa (SERPINA5)	TTK9LUQ	IPSP_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015497)
2	A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. Br J Pharmacol. 2020 May 1;10.1111/bph.15094.
3	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
4	Pfizer. Product Development Pipeline. March 31 2009.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359).
7	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
8	Company report (Portola)
9	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
10	Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81.
11	Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.
12	Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
13	Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24.